NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
Clinical Trials
22 trialsNCT02420613 2025-04-02
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03433183 2023-12-26
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT01767194 2022-10-24
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01051557 2021-07-19
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01467986 2020-10-06
RIST-rNB-2011
University of Regensburg
Phase 2 Completed
NCT00047073 2020-08-03
Sirolimus in Treating Patients With Glioblastoma Multiforme
Jonsson Comprehensive Cancer Center
Phase 1/2 Completed
NCT00509431 2020-07-31
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT01331135 2020-05-29
Aflac ST0901
Emory University
Phase 1 Completed
NCT01135563 2019-09-20
Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours
The Hospital for Sick Children
Phase 1 Completed
NCT00329719 2018-10-16
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00335764 2018-07-02
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00634270 2017-11-17
Protocol 102
University of Alabama at Birmingham
Phase 2 Completed
NCT01490476 2017-05-23
AFINF2
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT01522820 2016-10-04
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT01155258 2016-06-13
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Phase 1 Completed
NCT00112736 2015-06-15
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00821080 2015-05-01
Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
Massachusetts General Hospital
Phase 1 Completed
NCT00672243 2013-08-07
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Duke University
Phase 2 Completed
NCT00016328 2013-07-18
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00316849 2013-04-10
Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1 Completed
NCT01031901 2012-02-27
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
The University of Texas Health Science Center, Houston
Phase 1 Completed